Phaseline

Companies › Sichuan Huiyu Pharmaceutical

Sichuan Huiyu Pharmaceutical: clinical trials, targets and expected readouts

8 active drug programs in 13 registered trials: 8 Phase 1, 3 Phase 4, 1 Phase 3, 1 Phase 2; Oncology, Other, Hematology, Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HY-2003
Injection for reduction of submental fat accumulation
–Phase 1Moderate or Severe Submental FullnessDec 2026
HYP-2090PTSA
KRAS G12C inhibitor
KRASPhase 1SafetyDec 2026
Ferric Carboxymaltose Injection
Iron replacement therapy; ferric iron complexed with carboxymaltose
–Phase 1Healthy Adult; Postpartum Depression (PPD); Pulmonary Hypertension; Aortic Valve Stenosis …Jan 2027
HY07121–Phase 1SafetyMay 2027
HY0001a for injection–Phase 1Solid TumorJun 2027
HY05350
anti-MSLN antibody-drug conjugate
–Phase 1Advanced Solid TumorMar 2028
HYP-6589
EGFR kinase inhibitor
–Phase 1Solid TumorApr 2028
Ferric Derisomaltose Injection
Iron supplement - ferric ion delivered via derisomaltose complex
–Phase 1Iron Deficiency Anemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07790562Ferric Derisomaltose InjectionPhase 1Iron Deficiency AnemiaHematologySep 2026
NCT06756490HY-2003Phase 1Moderate or Severe Submental FullnessOncologyDec 2026
NCT06243354HYP-2090PTSAPhase 1SafetyOtherDec 2026
NCT07606105Ferric Carboxymaltose InjectionPhase 1Healthy AdultOtherJan 2027
NCT06639256HY07121Phase 1SafetyOtherMay 2027
NCT07069062HY0001a for injectionPhase 1Solid TumorOncologyJun 2027
NCT07217873Ferric Carboxymaltose InjectionPhase 2Scoliosis CorrectionHematologyAug 2027
NCT05744219Ferric Carboxymaltose InjectionPhase 3SurgeryOncologyDec 2027
NCT07083323HY05350Phase 1Advanced Solid TumorOncologyMar 2028
NCT06712680HYP-6589Phase 1Solid TumorOncologyApr 2028
NCT06833788Ferric Carboxymaltose InjectionPhase 4Postpartum Depression (PPD)PsychiatryJun 2028
NCT07359599Ferric Carboxymaltose InjectionPhase 4Pulmonary HypertensionCardiovascularJul 2028
NCT07370688Ferric Carboxymaltose InjectionPhase 4Aortic Valve StenosisCardiovascularJul 2028

Targets

KRAS (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.